| Combination of | |
|---|---|
| Efavirenz | Non-nucleoside reverse transcriptase inhibitor |
| Lamivudine | Nucleoside reverse transcriptase inhibitor |
| Tenofovir disoproxil | Nucleoside reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Symfi, Symfi Lo |
| Other names | EFV/3TC/TDF |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a618028 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Symfi among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[1][2][3] It combines efavirenz, lamivudine, and tenofovir disoproxil.[3] As of 2019[update], it is listed by the World Health Organization as an alternative first line option to dolutegravir/lamivudine/tenofovir.[4] It is taken by mouth.[1][2][3]
Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness.[3] Severe side effects may include depression, psychosis, or osteonecrosis.[3] In those with a history of epilepsy, it may increase the frequency of seizures.[3] Greater care should also be taken in those with kidney problems.[3] Its use during pregnancy appears to be unsafe.[1][2]
It is on the World Health Organization's List of Essential Medicines.[5] The combination received tentative approval in the United States in 2014,[6] and was granted approval in February 2018.[7][8] Its availability and importance is supported by Medecins Sans Frontieres.[3] It is available as a generic medication.[9][10][11]
Viruses
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
